Neurotoxicity of biologically targeted agents in pediatric cancer trials

Elizabeth M. Wells, Amulya A. Nageswara Rao, Joseph Scafidi, Roger J. Packer

Research output: Contribution to journalReview article

Abstract

Biologically targeted agents offer the promise of delivering specific anticancer effects while limiting damage to healthy tissue, including the central and peripheral nervous systems. During the past 5-10 years, these agents were examined in preclinical and adult clinical trials, and are used with increasing frequency in children with cancer. This review evaluates current knowledge about neurotoxicity from biologically targeted anticancer agents, particularly those in pediatric clinical trials. For each drug, neurotoxicity data are reviewed in adult (particularly studies of brain tumors) and pediatric studies when available. Overall, these agents are well tolerated, with few serious neurotoxic effects. Data from younger patients are limited, and more neurotoxicity may occur in the pediatric population because these agents target pathways that control not only tumorigenesis but also neural maturation. Further investigation is needed into long-term neurologic effects, particularly in children.

Original languageEnglish (US)
Pages (from-to)212-221
Number of pages10
JournalPediatric Neurology
Volume46
Issue number4
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Pediatrics
Clinical Trials
Neoplasms
Peripheral Nervous System
Brain Neoplasms
Antineoplastic Agents
Nervous System
Carcinogenesis
Central Nervous System
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Neurotoxicity of biologically targeted agents in pediatric cancer trials. / Wells, Elizabeth M.; Nageswara Rao, Amulya A.; Scafidi, Joseph; Packer, Roger J.

In: Pediatric Neurology, Vol. 46, No. 4, 01.04.2012, p. 212-221.

Research output: Contribution to journalReview article

Wells, Elizabeth M. ; Nageswara Rao, Amulya A. ; Scafidi, Joseph ; Packer, Roger J. / Neurotoxicity of biologically targeted agents in pediatric cancer trials. In: Pediatric Neurology. 2012 ; Vol. 46, No. 4. pp. 212-221.
@article{051fe25ef0ee430098a7add6cd865cba,
title = "Neurotoxicity of biologically targeted agents in pediatric cancer trials",
abstract = "Biologically targeted agents offer the promise of delivering specific anticancer effects while limiting damage to healthy tissue, including the central and peripheral nervous systems. During the past 5-10 years, these agents were examined in preclinical and adult clinical trials, and are used with increasing frequency in children with cancer. This review evaluates current knowledge about neurotoxicity from biologically targeted anticancer agents, particularly those in pediatric clinical trials. For each drug, neurotoxicity data are reviewed in adult (particularly studies of brain tumors) and pediatric studies when available. Overall, these agents are well tolerated, with few serious neurotoxic effects. Data from younger patients are limited, and more neurotoxicity may occur in the pediatric population because these agents target pathways that control not only tumorigenesis but also neural maturation. Further investigation is needed into long-term neurologic effects, particularly in children.",
author = "Wells, {Elizabeth M.} and {Nageswara Rao}, {Amulya A.} and Joseph Scafidi and Packer, {Roger J.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1016/j.pediatrneurol.2012.02.006",
language = "English (US)",
volume = "46",
pages = "212--221",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Neurotoxicity of biologically targeted agents in pediatric cancer trials

AU - Wells, Elizabeth M.

AU - Nageswara Rao, Amulya A.

AU - Scafidi, Joseph

AU - Packer, Roger J.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Biologically targeted agents offer the promise of delivering specific anticancer effects while limiting damage to healthy tissue, including the central and peripheral nervous systems. During the past 5-10 years, these agents were examined in preclinical and adult clinical trials, and are used with increasing frequency in children with cancer. This review evaluates current knowledge about neurotoxicity from biologically targeted anticancer agents, particularly those in pediatric clinical trials. For each drug, neurotoxicity data are reviewed in adult (particularly studies of brain tumors) and pediatric studies when available. Overall, these agents are well tolerated, with few serious neurotoxic effects. Data from younger patients are limited, and more neurotoxicity may occur in the pediatric population because these agents target pathways that control not only tumorigenesis but also neural maturation. Further investigation is needed into long-term neurologic effects, particularly in children.

AB - Biologically targeted agents offer the promise of delivering specific anticancer effects while limiting damage to healthy tissue, including the central and peripheral nervous systems. During the past 5-10 years, these agents were examined in preclinical and adult clinical trials, and are used with increasing frequency in children with cancer. This review evaluates current knowledge about neurotoxicity from biologically targeted anticancer agents, particularly those in pediatric clinical trials. For each drug, neurotoxicity data are reviewed in adult (particularly studies of brain tumors) and pediatric studies when available. Overall, these agents are well tolerated, with few serious neurotoxic effects. Data from younger patients are limited, and more neurotoxicity may occur in the pediatric population because these agents target pathways that control not only tumorigenesis but also neural maturation. Further investigation is needed into long-term neurologic effects, particularly in children.

UR - http://www.scopus.com/inward/record.url?scp=84859542719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859542719&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2012.02.006

DO - 10.1016/j.pediatrneurol.2012.02.006

M3 - Review article

C2 - 22490765

AN - SCOPUS:84859542719

VL - 46

SP - 212

EP - 221

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 4

ER -